Compositions and methods comprising binding proteins for adalimumab
US8969024B2 · kind B2 · utility
16Cited by
3References
14Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 27, 2008 |
| Grant date | Mar 3, 2015 |
| Priority date | — |
| Expiry date | May 10, 2032 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10S530/866
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
Compositions and methods comprising proteins that bind specifically to adalimumab are disclosed herein. Adalimumab is a monoclonal antibody specific for the cytokine TNF-α and was developed to treat TNF-α mediated inflammatory diseases. In one aspect of the instant invention, the binding proteins are antibodies directed toward adalimumab. These antibodies, including binding fragments thereof, can be used in a clinical setting as well as for research and development. For example, these anti-adalimumab antibodies can be employed to neutralize adalimumab.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.